Yes, I believe so too. Pharmaceutical products are a highly regulated environment everywhere, and especially US and China which are the numbers 1 and 2 markets.
No launch until 2024 and rather unusually the announcement doesnt distinguish between early, mid or late in that calendar year, so revenue generation from this approval is not immediate but nevertheless yet another incremental step forward for AFT. A bit surprising the market is not a bit more understanding but, like the coalition agreement, we will all be better informed as to how it is to be in future by the end of this week.